Trials / Unknown
UnknownNCT02921945
Efficacy and Safety Study of SCT800 for On-demand Treatment With in Patients With Hemophilia A
A Multi-center, Phase III, Non-controlled, Open-label Trial to Evaluate the Safety and Efficacy of SCT800 for On-demand Treatment in Previously Treated Patients With Hemophilia A
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Sinocelltech Ltd. · Industry
- Sex
- All
- Age
- 12 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
In this trial safety and efficacy of SCT800 (B-domain deleted recombinant factor VIII) is being evaluated in 50 subjects, 12 to 65 years of age, with moderate to severe Hemophilia A. These subjects will receive open label treatment with SCT800 for approximately 6 months for on-demand treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | SCT800 | recombinant human coagulation factor VIII |
Timeline
- Start date
- 2016-10-01
- Primary completion
- 2017-12-01
- Completion
- 2018-06-01
- First posted
- 2016-10-03
- Last updated
- 2016-10-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02921945. Inclusion in this directory is not an endorsement.